195 related articles for article (PubMed ID: 7036973)
21. A critical appraisal of the clinical efficiency of anti-platelet drugs.
Lecompte T; Samama M
Agents Actions Suppl; 1986; 20():203-14. PubMed ID: 3544741
[No Abstract] [Full Text] [Related]
22. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Antiplatelet Trialists' Collaboration
Br Med J (Clin Res Ed); 1988 Jan; 296(6618):320-31. PubMed ID: 3125883
[TBL] [Abstract][Full Text] [Related]
23. Role of platelet inhibitor therapy in myocardial infarction.
Stein B; Fuster V
Cardiovasc Drugs Ther; 1989 Dec; 3(6):797-813. PubMed ID: 2487543
[TBL] [Abstract][Full Text] [Related]
24. Antiplatelet therapy in the prevention of stroke.
Easton JD
Drugs; 1991; 42 Suppl 5():39-50. PubMed ID: 1726215
[TBL] [Abstract][Full Text] [Related]
25. Does platelet antiaggregant therapy lessen the severity of stroke?
Grotta JC; Lemak NA; Gary H; Fields WS; Vital D
Neurology; 1985 May; 35(5):632-6. PubMed ID: 3887210
[TBL] [Abstract][Full Text] [Related]
26. Secondary prevention of myocardial infarction--the present state of the ART.
Mitchell JR
Br Med J; 1980 May; 280(6223):1128-30. PubMed ID: 7000236
[No Abstract] [Full Text] [Related]
27. Status of antiplatelet drugs in coronary heart disease.
Mehta J; Mehta P
JAMA; 1979 Jun; 241(24):2649-51. PubMed ID: 439365
[No Abstract] [Full Text] [Related]
28. [Critical approach to a therapeutic trial in secondary prevention of cerebral ischemic accidents by antiaggregants].
Guiraud-Chaumeil B
Presse Med; 1983 Dec; 12(48):3045-8. PubMed ID: 6228912
[No Abstract] [Full Text] [Related]
29. [Antiplatelet drugs (author's transl)].
Dechavanne M; Follea G; Trzeciak MC
Anesth Analg (Paris); 1979; 36(7-8):283-7. PubMed ID: 525834
[TBL] [Abstract][Full Text] [Related]
30. [Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Offerhaus L
Ned Tijdschr Geneeskd; 1983 Apr; 127(16):673-9. PubMed ID: 6134240
[No Abstract] [Full Text] [Related]
31. Prevention of stroke.
Barnett HJ
Int Anesthesiol Clin; 1984; 22(3):11-29. PubMed ID: 6384054
[No Abstract] [Full Text] [Related]
32. [Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Oelz O
Schweiz Med Wochenschr; 1979 Mar; 109(10):348-53. PubMed ID: 424707
[TBL] [Abstract][Full Text] [Related]
33. [Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Bousser MG
Ann Med Interne (Paris); 1983; 134(2):79-83. PubMed ID: 6349464
[No Abstract] [Full Text] [Related]
34. [Therapy with anticoagulants and platelet aggregation inhibitors in extracranial vascular stenoses and occlusions].
Ostendorf P
Internist (Berl); 1979 Nov; 20(11):539-46. PubMed ID: 396265
[No Abstract] [Full Text] [Related]
35. Trials of antiplatelet drugs: some methodological considerations.
Armitage P
Rev Epidemiol Sante Publique; 1979 Sep; 27(2):87-90. PubMed ID: 538303
[No Abstract] [Full Text] [Related]
36. Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
McNicol GP
Lancet; 1980 Oct; 2(8197):736-8. PubMed ID: 6106840
[No Abstract] [Full Text] [Related]
37. [Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
Rühle H
Z Arztl Fortbild (Jena); 1985; 79(11):463-6. PubMed ID: 3901541
[No Abstract] [Full Text] [Related]
38. Role of blood platelets in coronary artery disease.
Haft JI
Am J Cardiol; 1979 Jun; 43(6):1197-206. PubMed ID: 35967
[TBL] [Abstract][Full Text] [Related]
39. Antiplatelet therapy.
Sloan RW
Am Fam Physician; 1981 Oct; 24(4):129-34. PubMed ID: 7025599
[TBL] [Abstract][Full Text] [Related]
40. Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Patrono C
Eur Heart J; 1986 Jun; 7(6):454-9. PubMed ID: 3525167
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
